Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma

Authors: Maryam Mardani, Azadeh Andisheh-Tadbir, Bijan Khademi, Mohammad Javad Fattahi, Shapour Shafiee, Maryam Asad-Zadeh

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Osteopontin (OPN) is a multifunctional glycophosphoprotein that was detected in many carcinomas, and it may have a prognostic role. The aim of this study was to determine osteopontin serum levels in patients with oral squamous cell carcinoma (OSCC) and investigated its correlation with clinicopathological features of tumor. Using an ELISA kit, we assessed and compared the circulating levels of OPN in blood serum of 45 oral squamous cell carcinoma patients with 45 healthy control samples. The serum osteopontin level in patients with OSCC was significantly higher (145.8 ± 14.6 ng/ml, n = 45) compared with the healthy controls (53.9 ± 9.6 ng/ml, n = 45, p < 0.001). Mean serum osteopontin level was significantly higher in patients with nodal metastasis (p = 0.03) and higher stage (p = 0.02). Findings of the present study suggest that OPN may have a potential role in pathogenesis of OSCC and it may be used as a tool for monitoring tumor progression.
Literature
1.
Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16:885–93.PubMedCrossRef
2.
Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475–82.PubMed
3.
4.
Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta (BBA)-Rev Cancer. 2001;1552:61–85.CrossRef
5.
Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2007;57:373–80.CrossRef
6.
Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol Eur Soc Surg Oncol Br Assoc Surg Oncol. 2005;31:555–8.
7.
Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, et al. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010;46:302–6.PubMedCrossRef
8.
Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46–52.PubMedCrossRef
9.
Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995;146:95.PubMedCentralPubMed
10.
Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 2013;14:288–94.PubMedCrossRef
11.
Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184–90.PubMedCrossRef
12.
Eto M, Kodama S, Nomi N, Uemura N, Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx. 2007;34:343–6.PubMedCrossRef
13.
Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, et al. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Pathol Med. 2007;36:30–4.CrossRef
14.
Routray S, Kheur SM, Kheur M. Osteopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias. Ann Diagn Pathol. 2013;17:421–4.PubMedCrossRef
15.
Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev. 2004;13:487–91.
16.
Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and cd44v9 in gastric cancer. Int J Cancer. 1998;79:127–32.PubMedCrossRef
17.
Saitoh Y, Kuratsu J-I, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma: its correlation with the malignancy. Lab Investig. 1995;72:55–63.PubMed
18.
Le Q-T, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59–67.PubMed
19.
Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003;198:107–17.PubMedCrossRef
20.
Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates mmp-2 and mmp-9 expressions in prostate cancer pc-3 cells. Cancer Lett. 2010;295:27–37.PubMedCrossRef
Metadata
Title
Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma
Authors
Maryam Mardani
Azadeh Andisheh-Tadbir
Bijan Khademi
Mohammad Javad Fattahi
Shapour Shafiee
Maryam Asad-Zadeh
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1506-4

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Review

The association between cytotoxic T lymphocyte-associated antigen-4 and cervical cancer

Research Article

Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis

Research Article

The variant interleukin 1f7 rs3811047 G>A was associated with a decreased risk of gastric cardiac adenocarcinoma in a Chinese Han population

Research Article

Common genetic variants at 1q22 and 10q23 and gastric cancer susceptibility in a Korean population

Research Article

MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3

Research Article

Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits